Dr. Musharraf Navaid, MD

Dr. Navaid practices at ECU Health Medical Center in Greenville, North Carolina, part of University Health Systems of Eastern Carolina.

Dr. Navaid's NPI, 1821061755, was assigned on February 10, 2006. Dr. Navaid holds North Carolina license 9801417.

Dr. Navaid's primary practice is ECU Health Medical Center, at 2100 Stantonsburg Rd, Greenville, NC 27834 in Pitt County. The practice phone is (252) 847-4100.

Dr. Navaid's primary practice is ECU Health Medical Center in Greenville, North Carolina, part of University Health Systems of Eastern Carolina. Dr. Navaid is also affiliated with ECU Health Edgecombe Hospital. The medical group on file is ECU Health. Dmand AI also links Dr. Navaid to 5 more group practices and clinics and 4 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Navaid practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Navaid's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Navaid is licensed in North Carolina.

CMS data shows 1,364 Medicare services from Dr. Navaid across 10 procedure codes in 2024, for 299 Medicare patients. Medicare paid $110,687 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 299 Medicare patients who saw Dr. Navaid in 2024. The largest group is 75 to 84, with 121 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 16% are also on Medicaid. Their average risk score is 2.44, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Navaid's median patient age at 72, with 39% women.

In 2024, Dr. Navaid wrote 1,802 Medicare Part D claims for 195 patients. 75% of them were for generic drugs. CMS names the drug for 1,567 of them, across 39 drugs with 11 or more claims each, at $3,378,890 in total drug cost. In 2023, CMS named 1,384 claims across 30 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Dr. Navaid for performance year 2024, reported through an alternative payment model (APM). Dr. Navaid accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Navaid as offering telehealth.

Dmand AI links 9 papers to Dr. Navaid, published from 2020 to 2025. 2021 was the busiest year, with 3. The most frequent topics are SEER Program. Dr. Navaid has published most often in Cancers (Basel). Dr. Navaid's most frequent co-authors are Tomi Jun, Uqba Khan, MD and Thomas Urban Marron, MD, PhD.

Dmand AI links Dr. Navaid to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Lymphatic Metastasis and Carcinoma, Renal Cell.

CMS Open Payments shows 568 general payments to Dr. Navaid from 54 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 93% of the total. Bristol-Myers Squibb Company paid the most, $1,121.